VolitionRx Partners with Sysmex to Advance Nu.Q® NETs Assay Development

VolitionRx Limited (NYSE American: VNRX) has entered into a collaboration with Sysmex (TYO: 6869) to optimize its proprietary Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform, the companies announced. This partnership aligns with Volition’s strategy of licensing its Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities, and installed analyzer base to accelerate development and commercialization.

According to Volition, the collaboration has progressed beyond assay transfer and is now in the optimization phase for diseases associated with NETosis, a biological process implicated in conditions such as sepsis and other acute and chronic diseases. The company believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring, and address a commercial opportunity with an estimated total addressable market of $3.8 billion.

NETosis is a form of cell death that releases neutrophil extracellular traps (NETs), which play a role in inflammation and thrombosis. The Nu.Q® NETs assay detects specific histone modifications associated with NETosis, offering potential for earlier diagnosis and better monitoring of disease progression.

This collaboration is significant because it leverages Sysmex’s global reach and expertise in diagnostics. Sysmex is a leading provider of laboratory diagnostics and has a strong installed base of analyzers worldwide. By optimizing the assay on Sysmex’s platform, Volition aims to facilitate regulatory approvals and market adoption, ultimately bringing the test to clinicians and patients faster.

The market opportunity for NETosis-related diagnostics is substantial. Sepsis alone affects millions of people annually and is a leading cause of death in hospitals. Improved diagnostic tools could enable earlier intervention, potentially saving lives and reducing healthcare costs. The $3.8 billion addressable market reflects the broad applicability of the Nu.Q® NETs assay across multiple acute and chronic conditions.

VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

For further information about this collaboration and Volition’s technology, visit the company’s website at https://volition.com/. The full press release is available at https://ibn.fm/TSMG4.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VolitionRx Partners with Sysmex to Advance Nu.Q® NETs Assay Development.

The post VolitionRx Partners with Sysmex to Advance Nu.Q® NETs Assay Development appeared first on citybuzz.